
Emestedastat did not significantly slow disease progression, but a prespecified analysis showed a higher rate of zero CDR-SB progression.
Are you up-to-date on the latest findings in mild cognitive impairment, dementia, and depression in elderly patients?
View the slides in PDF format.


